AI Article Synopsis
- Researchers found that certain blood tests called serum tumor markers can help predict how well lung cancer patients will respond to treatments like chemotherapy and immunotherapy.
- They looked at many studies and found that high levels of a marker called CYFRA 21-1 often mean a worse outlook for patients, while another marker, CA125, shows potential for tracking progress in patients getting immunotherapy.
- The study suggests that using a combination of these markers might give better predictions, and future research should have clearer methods to compare results more accurately.
Article Abstract
Background: Therapeutic possibilities for non-small cell lung cancer (NSCLC) have considerably increased during recent decades.
Objective: To summarize the prognostic relevance of serum tumor markers (STM) for early and late-stage NSCLC patients treated with classical chemotherapies, novel targeted and immune therapies.
Methods: A PubMed database search was conducted for prognostic studies on carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), neuron-specific enolase, squamous-cell carcinoma antigen, progastrin-releasing-peptide, CA125, CA 19-9 and CA 15-3 STMs in NSCLC patients published from 2008 until June 2022.
Results: Out of 1069 studies, 141 were identified as meeting the inclusion criteria. A considerable heterogeneity regarding design, patient number, analytical and statistical methods was observed. High pretherapeutic CYFRA 21-1 levels and insufficient decreases indicated unfavorable prognosis in many studies on NSCLC patients treated with chemo-, targeted and immunotherapies or their combinations in early and advanced stages. Similar results were seen for CEA in chemotherapy, however, high pretherapeutic levels were sometimes favorable in targeted therapies. CA125 is a promising prognostic marker in patients treated with immunotherapies. Combinations of STMs further increased the prognostic value over single markers.
Conclusion: Protein STMs, especially CYFRA 21-1, have prognostic potential in early and advanced stage NSCLC. For future STM investigations, better adherence to comparable study designs, analytical methods, outcome measures and statistical evaluation standards is recommended.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/TUB-230009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!